Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates

NACompletedINTERVENTIONAL
Enrollment

436

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Cardiovascular DiseasesHeart DiseasesObesity
Interventions
DRUG

Sibutramine

At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.

BEHAVIORAL

Behavioral Smoking Cessation Program

Both groups of participants will take part in a behavioral smoking cessation program.

Trial Locations (1)

38163

University of Tennessee Health Science Center, Memphis

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Tennessee

OTHER

NCT00037752 - Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates | Biotech Hunter | Biotech Hunter